Skip to main content

Clinical Trials Using Carboplatin

Review the clinical trials studying carboplatin on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 267

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early Triple Negative Breast Cancer
Status: Active
Location: 957 locations
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Status: Active
Location: 1049 locations
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy will Improve Outcomes Compared to Cabazitaxel Alone in People with Castrate-Resistant Prostate Cancer that has Spread Beyond the Prostate to Other Parts of the Body
Status: Active
Location: 468 locations
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Status: Active
Location: 446 locations
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients with Germ Cell Tumors
Status: Active
Location: 470 locations
Testing the addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Status: Active
Location: 376 locations
Comparing Impact of Treatment Before or After Surgery in Patients with Stage II-IIIB Resectable Non-small Cell Lung Cancer
Status: Active
Location: 339 locations
Chemotherapy Combined with Immunotherapy versus Immunotherapy alone for Older Adults with Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Status: Active
Location: 298 locations
Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung
Status: Active
Location: 229 locations
A Study of Combination Chemotherapy for Patients with Newly Diagnosed DAWT and Relapsed FHWT
Status: Active
Location: 175 locations
Dinutuximab with Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children with Newly Diagnosed High Risk Neuroblastoma
Status: Active
Location: 151 locations
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People with High-Risk Neuroblastoma (NBL)
Status: Active
Location: 147 locations
A Study of a New Way to Treat Children and Young Adults with a Brain Tumor Called NGGCT
Status: Active
Location: 144 locations
Carboplatin Chemotherapy before Surgery for Patients with High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
Status: Active
Location: 167 locations
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) with the Contrast Agent Iohexol
Status: Active
Location: 161 locations
A Study Using Risk Factors to Determine Treatment for Children with Favorable Histology Wilms Tumors (FHWT)
Status: Active
Location: 128 locations
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy with Radiation after Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
Status: Active
Location: 137 locations
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients with Low-Grade Glioma
Status: Active
Location: 119 locations
A Study of Lower Radiotherapy Dose to Treat Children with CNS Germinoma
Status: Active
Location: 84 locations
Combining Radiation Therapy with Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Active
Location: 81 locations
Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer
Status: Active
Location: 75 locations
Targeted Treatment for Metastatic Prostate Cancer, PREDICT Trial
Status: Active
Location: 75 locations
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy after Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
Status: Active
Location: 71 locations
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Status: Active
Location: 43 locations
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Status: Active
Location: 35 locations